Perspectives

New year, new opportunities: M&A life sciences trends

Explore our 2024 life sciences M&A predictions

Life sciences M&A was a bright spot across the wider dealmaking world in 2023. Will this positive trend continue over the next 12 months? We think so. We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what else we expect this year.

Life sciences M&A: Looking back at 2023

Life sciences M&A dealmaking in 2023 was brighter than many expected, eclipsing the $135 billion figure from 2022, with $163 billion worth of deals announced through the end of October. The primary driver of strength in 2023 was the pharmaceutical segment, where 2023 M&A activity exceeded the same period in 2022 by 35%.

 

Based on these key life sciences trends, Deloitte sees momentum continuing into 2024.

2024 annual life sciences M&A predictions

Another positive year ahead

2023 will not go down as a banner year for life sciences M&A, but overall, deal value and transaction activity were resilient in spite of several macro headwinds that curtailed M&A activity in other sectors. With MedTech potentially rebounding, we think the life sciences M&A backdrop for 2024 looks favorable if not slightly more positive than it did heading into 2023.

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?